🚀 VC round data is live in beta, check it out!
Abeona Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Abeona Therapeutics and similar public comparables like Animalcare Group, Journey Medical, Oryzon Genomics, Kala Bio and more.
Abeona Therapeutics Overview
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Founded
1974
HQ
Employees
136
Website
Financials (LTM)
EV
$80M
Abeona Therapeutics Financials
Abeona Therapeutics reported last 12-month revenue of $19M.
In the same LTM period, Abeona Therapeutics generated $15M in gross profit and $44M in net income.
Revenue (LTM)
Abeona Therapeutics P&L
In the most recent fiscal year, Abeona Therapeutics reported revenue of $6M and EBITDA of $79M.
Abeona Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $19M | XXX | $6M | XXX | XXX | XXX |
| Gross Profit | $15M | XXX | $2M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | — | XXX | $79M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 1350% | XXX | XXX | XXX |
| EBIT Margin | (421%) | XXX | (1537%) | XXX | XXX | XXX |
| Net Profit | $44M | XXX | $71M | XXX | XXX | XXX |
| Net Margin | 230% | XXX | 1223% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Abeona Therapeutics Stock Performance
Abeona Therapeutics has current market cap of $263M, and enterprise value of $80M.
Market Cap Evolution
Abeona Therapeutics' stock price is $4.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $80M | $263M | 0.0% | XXX | XXX | XXX | $1.31 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAbeona Therapeutics Valuation Multiples
Abeona Therapeutics trades at 4.1x EV/Revenue multiple, and 1.0x EV/EBITDA.
EV / Revenue (LTM)
Abeona Therapeutics Financial Valuation Multiples
As of March 25, 2026, Abeona Therapeutics has market cap of $263M and EV of $80M.
Equity research analysts estimate Abeona Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Abeona Therapeutics has a P/E ratio of 5.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $263M | XXX | $263M | XXX | XXX | XXX |
| EV (current) | $80M | XXX | $80M | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 13.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBIT | (1.0x) | XXX | (0.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | 33.3x | XXX | XXX | XXX |
| P/E | 5.9x | XXX | 3.7x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Abeona Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Abeona Therapeutics Margins & Growth Rates
Abeona Therapeutics' revenue in the last 12 month grew by 335%.
Abeona Therapeutics' revenue per employee in the last FY averaged $0.1M.
Abeona Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 335% | XXX | 1002% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 1350% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (239%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 354% | XXX | 1117% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 136% | XXX | 461% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1578% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Abeona Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Animalcare Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Journey Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Oryzon Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kala Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Ourofino | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abeona Therapeutics M&A Activity
Abeona Therapeutics acquired XXX companies to date.
Last acquisition by Abeona Therapeutics was on XXXXXXXX, XXXXX. Abeona Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Abeona Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAbeona Therapeutics Investment Activity
Abeona Therapeutics invested in XXX companies to date.
Abeona Therapeutics made its latest investment on XXXXXXXX, XXXXX. Abeona Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Abeona Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Abeona Therapeutics
| When was Abeona Therapeutics founded? | Abeona Therapeutics was founded in 1974. |
| Where is Abeona Therapeutics headquartered? | Abeona Therapeutics is headquartered in United States. |
| How many employees does Abeona Therapeutics have? | As of today, Abeona Therapeutics has over 136 employees. |
| Who is the CEO of Abeona Therapeutics? | Abeona Therapeutics' CEO is Vishwas Seshadri. |
| Is Abeona Therapeutics publicly listed? | Yes, Abeona Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Abeona Therapeutics? | Abeona Therapeutics trades under ABEO ticker. |
| When did Abeona Therapeutics go public? | Abeona Therapeutics went public in 1980. |
| Who are competitors of Abeona Therapeutics? | Abeona Therapeutics main competitors are Animalcare Group, Journey Medical, Oryzon Genomics, Kala Bio. |
| What is the current market cap of Abeona Therapeutics? | Abeona Therapeutics' current market cap is $263M. |
| What is the current revenue of Abeona Therapeutics? | Abeona Therapeutics' last 12 months revenue is $19M. |
| What is the current revenue growth of Abeona Therapeutics? | Abeona Therapeutics revenue growth (NTM/LTM) is 335%. |
| What is the current EV/Revenue multiple of Abeona Therapeutics? | Current revenue multiple of Abeona Therapeutics is 4.1x. |
| Is Abeona Therapeutics profitable? | Yes, Abeona Therapeutics is net-income-positive (as of the last 12 months). |
| What is the current net income of Abeona Therapeutics? | Abeona Therapeutics' last 12 months net income is $44M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.